Vigeo Therapeutics, Inc.
Funding rounds
2 counted as startup funding. Open the number of investors for the round's details.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Vigeo Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Mar 2021).
SEC Form D · Mar 2021
The industry group it chose in its notices: Biotechnology.
SEC Form D · Mar 2021
Products and services#
No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).
Investors#
No investor of Vigeo Therapeutics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Jing Watnick | Executive officer | Mar 2021 |
| Peter B. Finn | Executive officer | Mar 2021 |
| Peter B Finn | Executive officer | Jun 2015 |
| James E. Mahoney | Director | Mar 2021 |
| Jing Watnick | Director | Mar 2021 |
| Stephanie E. O'Brien | Director | Mar 2021 |
| Westerly E. Nolin, Ph.D. | Director | Mar 2021 |
| Jason Dinges | Director | Jun 2015 |
| Peter B Finn | Director | Jun 2015 |
| Stephanie O'Brien | Director | Jun 2015 |